Arbutus Biopharma Corporation
ABUS
NGS
Sector: Healthcare
Industry: Biotechnology
2.04
USD
0.11
(5.70%)
Optionable: Yes Market Cap: 289 M 90-day average vol: 775,643
Previous close: 1.93 Open: 1.9 Bid: 2.1 Ask: 2.1
52 week range
1.85 6.50
Last updated: Thursday 29th September 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Financials
ABUS Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 14 M | 15 M | 15 M | 23 M | 1 M | 11 M | 6 M | 6 M | 7 M | 11 M |
| Cost of sales | 17 M | 21 M | 38 M | 51 M | 60 M | 61 M | 56 M | 56 M | 45 M | -3 M |
| Gross operating profit | -4 M | -6 M | -24 M | -28 M | -60 M | -52 M | -52 M | -52 M | -41 M | 11 M |
| Selling Gen & administrative expense | -38 M | 6 M | 9 M | 26 M | 39 M | 16 M | 16 M | 18 M | 15 M | 17 M |
| Research & development expense | 18 M | 21 M | 39 M | 52 M | 61 M | 63 M | 58 M | 58 M | 49 M | 66 M |
| Operating income | 33 M | -12 M | -33 M | -55 M | -100 M | -70 M | -70 M | -71 M | -57 M | -72 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -4 M | -2 M | -7 M | -24 M | -390 M | -40 M | 6 M | -95 M | -3 M | -2 M |
| Pre-tax Income (EBT) | 30 M | -14 M | -39 M | -79 M | -489 M | -109 M | -61 M | -166 M | -64 M | -76 M |
| Income taxes | 0 | 0 | 0 | -16 M | -105 M | -24 M | -4 M | -13 M | 0 | 0 |
| Net income from total operations | 30 M | -14 M | -39 M | -63 M | -384 M | -84 M | -57 M | -154 M | -64 M | -76 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | 30 M | -14 M | -39 M | -63 M | -384 M | -84 M | -57 M | -154 M | -64 M | -76 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | 911000 | 10 M | 11 M | 3 M | N/A |
| Net income available for common | 30 M | -14 M | -39 M | -63 M | -384 M | -85 M | -67 M | -165 M | -64 M | -76 M |
| Depreciation | 866000 | 613000 | 529000 | 589000 | 1 M | 2 M | 2 M | 2 M | 2 M | 3 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | 34 M | -12 M | -32 M | -78 M | -488 M | -106 M | -59 M | -162 M | -58 M | -72 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 2.18 | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | -2.89 | -1 | -0.83 |
| Diluted EPS total | 2.09 | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | -2.89 | -1 | -0.83 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today